Randomized controlled trial evaluated histologic inflammation in Crohn’s disease, revealing mirikizumab improves response and remission.
Introduction: Mirikizumab (MIRI) increased histologic response (H-Res) and remission (H-Rem) relative to placebo (PBO) in the Phase 2 SERENITY trial.
No takes yet. Share an insight, caveat, or question.
Jairath et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: